Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UC Davis
Dates
study started
completion around

Description

Summary

Official Title

A Phase 1b Study Of ABBV-744 Alone Or In Combination With Ruxolitinib Or Navitoclax In Subjects With Myelofibrosis

Keywords

Myelofibrosis (MF), ABBV-744, Navitoclax, Ruxolitinib, ABT-263, Cancer, Myelofibrosis, MF, Primary Myelofibrosis, Segment A: ABBV-744 Monotherapy, Segment B: Ruxolitinib + ABBV-744 "Add on" Therapy, Segment C: ABBV-744 + Navitoclax, Segment D: ABBV-744 + Ruxolitinib

Eligibility

Locations

  • University of California, Davis Comprehensive Cancer Center /ID# 221790
    Sacramento California 95817 United States
  • Oregon Health and Science University /ID# 221801
    Portland Oregon 97239 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
AbbVie
ID
NCT04454658
Phase
Phase 1 research study
Study Type
Interventional
Participants
About 21 people participating
Last Updated